Sanbongi Yumiko, Suzuki Takahisa, Osaki Yumi, Senju Nami, Ida Takashi, Ubukata Kimiko
Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan.
Antimicrob Agents Chemother. 2006 Jul;50(7):2487-92. doi: 10.1128/AAC.01316-05.
A total of 621 clinical isolates of Haemophilus influenzae collected in Japan between 1995 and 2003 were studied for their susceptibilities to several antimicrobial agents, beta-lactamase production, and amino acid substitutions in penicillin-binding protein 3 (PBP 3). Over the four study periods (first period, 1995 to 1996; second period, 1997 to 1998; third period, 2000 to 2001; fourth period, 2002 to 2003), the susceptibilities to beta-lactam agents decreased and the incidence of isolates with substitutions at positions 377, 385, 389, 517, and/or 526 in PBP 3 increased from 28.8% to 52.0%. Five hundred seventy-one beta-lactamase-nonproducing isolates were grouped into 18 classes, based on the pattern of the five mutations in PBP 3. The Asp526Lys substitution led to 6.0-, 4.3-, 2.4-, and 5.4-fold increases in amoxicillin-clavulanic acid, cefdinir, cefditoren, and faropenem resistance, respectively. PBP 3 with multiple substitutions (Met377Ile, Ser385Thr, and/or Leu389Phe) together with Asp526Lys resulted in increased resistance compared to that for PBP 3 with the Asp526Lys substitution alone. These results indicate that mutations at these five positions increased resistance to most beta-lactams. Although a significant change in the prevalence of beta-lactamase-producing strains was not observed, the proportions of those possessing both PBP 3 alterations and beta-lactamase production have slightly increased (from 1.4% to 5.0%). The ROB-1 beta-lactamase was rare, but this is the first report of this beta-lactamase in Japan.
对1995年至2003年期间在日本收集的621株流感嗜血杆菌临床分离株进行了研究,检测它们对几种抗菌药物的敏感性、β-内酰胺酶的产生情况以及青霉素结合蛋白3(PBP 3)中的氨基酸替代情况。在四个研究阶段(第一阶段,1995年至1996年;第二阶段,1997年至1998年;第三阶段,2000年至2001年;第四阶段,2002年至2003年),分离株对β-内酰胺类药物的敏感性下降,PBP 3中377、385、389、517和/或526位发生替代的分离株发生率从28.8%增加到52.0%。根据PBP 3中五个突变的模式,将571株不产β-内酰胺酶的分离株分为18类。Asp526Lys替代分别导致阿莫西林-克拉维酸、头孢地尼、头孢妥仑和法罗培南的耐药性增加6.0倍、4.3倍、2.4倍和5.4倍。与仅具有Asp526Lys替代的PBP 3相比,具有多个替代(Met377Ile、Ser385Thr和/或Leu389Phe)以及Asp526Lys的PBP 3导致耐药性增加。这些结果表明,这五个位置的突变增加了对大多数β-内酰胺类药物的耐药性。虽然未观察到产β-内酰胺酶菌株的流行率有显著变化,但同时具有PBP 3改变和产β-内酰胺酶的菌株比例略有增加(从1.4%增至5.0%)。ROB-1β-内酰胺酶很少见,但这是该β-内酰胺酶在日本的首次报道。